HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) All Versions of this Article: adc.2005.092817v1 92/3/F204    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in ADC Online Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Paradisis, M. Articles by Osborn, D. Search for Related Content PubMed PubMed Citation Articles by Paradisis, M. Articles by Osborn, D.

Population pharmacokinetics and dosing regimen design of milrinone in preterm infants

¹ Department of Newborn Care, RPA Women and Babies Hospital, Camperdown, NSW, Australia
² Department of Neonatal Medicine, Royal North Shore Hospital, St Leonards, NSW, Australia
³ Faculty of Medicine, University of Sydney. Sydney, NSW, Australia
⁴ Faculty of Pharmacy, University of Sydney. Sydney, NSW. Australia

Correspondence to:
Correspondence to:
Clinical Associate Professor Nick Evans
Department of Newborn Care, Royal Prince Alfred Hospital, Camperdown, NSW. 2050 Australia; nevans{at}med.usyd.edu.au

Aims: To define the pharmacokinetics of milrinone in very preterm infants and determine an optimal dose regimen to prevent low systemic blood flow in the first 12 h after birth.

Methods: A prospective open-labelled, dose-escalation pharmacokinetic study was undertaken in two stages. In stage one, infants received milrinone at 0.25 µg/kg/min (n = 8) and 0.5 µg/kg/min (n = 11) infused from 3 to 24 h of age. Infants contributed 4–5 blood samples for concentration–time data which were analysed using a population modelling approach. A simulation study was used to explore the optimal dosing regimen to achieve target milrinone concentrations (180–300 ng/ml). This milrinone regimen was evaluated in stage two (n = 10).

Results: Infants (n = 29) born before 29 weeks gestation were enrolled. Milrinone pharmacokinetics were described using a one-compartment model with first-order elimination rate, with a population mean clearance (CV%) of 35 ml/h (24%) and volume of distribution of 512 ml (21%) and estimated half-life of 10 h. The 0.25 and 0.5 µg/kg/min dosage regimens did not achieve optimal milrinone concentration-time profiles to prevent early low systemic blood flow. Simulation studies predicted a loading infusion (0.75 µg/kg/min for 3 h) followed by maintenance infusion (0.2 µg/kg/min until 18 h of age) would provide an optimal milrinone concentration profile. This was confirmed in stage two of the study.

Conclusion: Population pharmacokinetic modelling in the preterm infant has established an optimal dose regimen for milrinone that increases the likelihood of achieving therapeutic aims and highlights the importance of pharmacokinetic studies in neonatal clinical pharmacology.

Abbreviations: FOCE, first-order approximation with condition estimation; SVC, superior vena cava

Keywords: FOCE; first-order approximation with condition estimation; HPLC; high performance liquid chromatography; P/IVH; peri/intraventricular haemorrhage; SVC; superior vena cava